Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635) (RNAZ)
Activity window: Oct. 25, 2025 to Oct. 24, 2026
Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.
The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: May. 15, 2026. These dates describe different events.
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| May. 15, 2026 | CORRESP | Neutral/Informational | Moderate | Transcode Therapeutics, Inc. has submitted a request to the SEC for the acceleration of the effectiveness of their Registration Statement on Form S-1, seeking to have it declared … | Read Filing EDGAR |
| May. 15, 2026 | CORRESP | Neutral/Informational | Moderate | Transcode Therapeutics, Inc. has submitted a request to the SEC for the acceleration of the effectiveness of their Registration Statement on Form S-3. They are seeking to have the… | Read Filing EDGAR |
| May. 6, 2026 | UPLOAD | Neutral/Informational | Low | The SEC correspondence dated May 6, 2026, informs Philippe P. Calais, CEO of TransCode Therapeutics, Inc., that the SEC has not reviewed and will not review their registration sta… | Read Filing EDGAR |
| May. 6, 2026 | UPLOAD | Concern from SEC | Moderate | The SEC has communicated to Transcode Therapeutics, Inc. that it will not review the company's registration statement filed on May 1, 2026. The letter emphasizes the company's res… | Read Filing EDGAR |
| Dec. 18, 2025 | CORRESP | Neutral/Informational | Moderate | Transcode Therapeutics, Inc. has submitted a request to the SEC for the acceleration of the effective date of their registration statement on Form S-3. They are seeking to have th… | Read Filing EDGAR |